<DOC>
	<DOC>NCT01948791</DOC>
	<brief_summary>To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration</brief_summary>
	<brief_title>16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Key Have a diagnosis of dementia of the Alzheimer's type according to the DSMIV criteria and have a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria MMSE score of ≥ 10 and ≤ 26 The treatment naïve patient and the one who have stopped the donepezil, galantamine, huperzine A, or memantine at least 2 weeks Be in stable medical condition Have signed off informed consent form by patients or his/her legal guardian Key Severe AD Patients with a history of cerebrovascular disease, Active or uncontrolled epilepsy, Active hypothyroidism, asthma, CNS infection, other Neurodegenerative disorders, an advanced, severe, progressive, or unstable medical condition Attending other clinical trials or taking other clinical trial drugs A score of &gt; 4 on the Modified Hachinski Ischemic Scale (MHIS); Patients who is using any AChEI or memantine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>ENA713</keyword>
	<keyword>Chinese patients</keyword>
	<keyword>INSTINCT</keyword>
</DOC>